SOMERSET, N.J.--(BUSINESS WIRE)--Jan 3, 2023--

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will participate at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 at 5:15 p.m. EST.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230103005777/en/

CONTACT: Investors:

Paul Surdez, Catalent, Inc.

(732) 537-6325

investors@catalent.com

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH OTHER HEALTH HEALTH PHARMACEUTICAL

SOURCE: Catalent, Inc.

Copyright Business Wire 2023.

PUB: 01/03/2023 05:15 PM/DISC: 01/03/2023 05:15 PM

http://www.businesswire.com/news/home/20230103005777/en